Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica

L. Pulsatelli, G. Peri, P. Macchioni, L. Boiardi, C. Salvarani, F. Cantini, A. Mantovani, R. Meliconi

Research output: Contribution to journalArticlepeer-review


Objectives: To evaluate PTX3 feasibility to provide a prognostic tool in PMR clinical practice. Methods: Circulating PTX3 levels were measured in 93 PMR patients at disease onset and during corticosteroid therapy and in 46 normal controls (NC) by ELISA. Results: No difference in PTX3 concentrations was observed between NC and PMR either at disease onset and during follow-up or between groups of patients defined according to the presence of recurrence/relapse. Conclusions: PTX3 serum levels do not increase significantly in active PMR. Further studies on patients with giantcell arteritis could evaluate whether large vessel involvement may be associated to increased PTX3 levels.

Original languageEnglish
Pages (from-to)756-758
Number of pages3
JournalClinical and Experimental Rheumatology
Issue number5
Publication statusPublished - 2010


  • Biological marker
  • Polymyalgia reumatica
  • PTX3

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy


Dive into the research topics of 'Serum levels of long pentraxin PTX3 in patients with polymyalgia rheumatica'. Together they form a unique fingerprint.

Cite this